Suntory is betting on health foods and over-the-counter pharmaceuticals to hedge its fortunes and counter possible weakness in its main business lines.
So the company has started acquiring Daiichi Sankyo Healthcare, an OTC drugmaker, for ?246.5 billion ($1.5 billion), and will own the whole company in about three years.
“Looking at the next 10 years, we are aiming to roughly double sales through synergy and growth of existing products,” Toru Miyanaga, Suntory’s chief strategy officer, said last week, in speaking about Daiichi Sankyo Healthcare.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.